Quantitative PCR and immunohistochemical analyses of HMGB1 and RAGE expression in canine disseminated histiocytic sarcoma (Malignant histiocytosis)

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1541-1548

  Sterenczak, Katharina A ^a   Kleinschmidt, Sven ^a   Wefstaedt, Patrick ^a   Eberle, Nina ^a   Hewicker Trautwein, Marion ^a   Bullerdiek, Jörn ^a,b   Nolte, Ingo ^a   Escobar, Hugo Murua ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

Disseminated histiocytic sarcoma; HMGB1; Immunohistochemistry; Quantitative PCR; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN;

ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CANINE DISSEMINATED HISTOCYTIC SARCOMA; CARCINOGENESIS; CONTROLLED STUDY; DOG DISEASE; FEMALE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LUNG; LYMPH NODE; MALE; MALIGNANT HISTIOCYTOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; SPLEEN; TUMOR GROWTH;

ANIMALS; DOGS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTIOCYTIC SARCOMA; HMGB1 PROTEIN; IMMUNOENZYME TECHNIQUES; MALE; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79958099240     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Fulmer AK and Mauldin GE: Canine histiocytic neoplasia: an overview. Can Vet J 48(10): 1041-1043, 1046-1050, 2007.
2. Withrow S and Vail DM: Withrow and MacEwen's Small Animal Clinical Oncology, fourth edition. St. Louis: Saunders Elsevier; 2007.
3. Rosin A, Moore P and Dubielzig R: Malignant histiocytosis in Bernese Mountain dogs. J Am Vet Med Assoc 188(9): 1041-1045, 1986.
4. Affolter VK and Moore PF: Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol 39(1): 74-83, 2002.
5. Soller JT, Murua Escobar H, Janssen M, Fork M, Bullerdiek J and Nolte I: Cytokine genes single nucleotide polymorphism (SNP) screening analyses in canine malignant histiocytosis. Anticancer Res 26(5A): 3417-3420, 2006. (Pubitemid 44701517)
6. Abadie J, Hedan B, Cadieu E, De Brito C, Devauchelle P, Bourgain C, Parker HG, Vaysse A, Margaritte-Jeannin P, Galibert F, Ostrander EA and Andre C: Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. J Hered 100(Suppl 1): 19-27, 2009.
7. Nielsen L, Andreasen SN, Andersen SD and Kristensen AT: Malignant histiocytosis and other causes of death in Bernese mountain dogs in Denmark. Vet Record 166(7): 199-202, 2010.
8. Ng-Cheng-Hin B, O'Hanlon-Brown C, Alifrangis C and Waxman J: Langerhans cell histiocytosis: old disease new treatment. Qjm 104(2): 89-96, 2011.
9. Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, Bucsky P, Egeler RM, Elinder G, Gadner H, Gresik M, Henter JI, Imashuku S, Janka-Schaub G, Jaffe R, Ladisch S, Nezelof C and Pritchard J: Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 29(3): 157-166, 1997.
10. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S and Bullerdiek J: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166(4): 1259-1263, 2005. (Pubitemid 40524448)
11. Muller S, Ronfani L and Bianchi ME: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255(3): 332-343, 2004. (Pubitemid 38315274)
12. van Beijnum JR, Buurman WA and Griffioen AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11(1): 91-99, 2008.
13. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D and Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267(21): 14998-15004, 1992.
14. Murua Escobar H, Soller JT, Sterenczak KA, Sperveslage JD, Schlueter C, Burchardt B, Eberle N, Fork M, Nimzyk R, Winkler S, Nolte I and Bullerdiek J: Cloning and characterization of the canine receptor for advanced glycation end products. Gene 369: 45-52, 2006. (Pubitemid 43327330)
15. Buckley ST and Ehrhardt C: The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2070: 917108, 11 pages, 2009.
16. Sims GP, Rowe DC, Rietdijk ST, Herbst R and Coyle AJ: HMGBl and RAGE in inflammation and cancer. Ann Rev Immunol 28: 367-388, 2010.
17. Han SH, Kim YH and Mook-Jung I: RAGE: The beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 31(2): 91-97, 2011.
18. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA and Rovere-Querini P: Release of high mobility group box 1 by dendritic cells controls T cell activation via me receptor for advanced glycation end products. J Immunol 174(12): 7506-7515, 2005. (Pubitemid 40806253)
19. Altmann S, Lange S, Pommerencke J, Murua Escobar H, Bullerdiek J, Nolte I, Freund M and Junghanss C: High Mobility Group Box 1-Protein expression in canine haematopoietic cells and influence on canine peripheral blood mononuclear cell proliferative activity. Vet Immunol Immunopathol 126(3-4): 367-372, 2008.
20. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA and Rovere- Querini P: The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81(1): 84-91, 2007. (Pubitemid 46021256)
21. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M and Oppenheim JJ: High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 81(1): 59-66, 2007. (Pubitemid 46021253)
22. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus A, Bianchi ME, Rovere-Querini P and Del Maschio A: Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol 180(4): 2270-2275, 2008.
23. Laman JD, Leenen PJ, Annels NE, Hogendoorn PC and Egeler RM: Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol 24(4): 190-196, 2003.
24. Murua Escobar H, Meyer B, Richter A, Becker K, Flohr AM, Bullerdiek J and Nolte I: Molecular characetrization of the canine HMGB1. Cytogenet Genome Res 101: 33-38, 2003.
25. Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT, Eberle N, Nolte I, Bullerdiek J and Murua Escobar H: Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 434(1-2): 35-42, 2009.
26. von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M and Georgii A: Tyramine amplification technique in routine immunohistochemistry. J Histochem Cytochem 45(11): 1455-1459, 1997.
27. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30(9): e36, 10 pages, 2002.
28. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7): RESEARCH0034, 12 pages, 2002.
29. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ and Lotze MT: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transi Med 7: 17, 21 pages, 2009.
30. Schraml P, Bendik I and Ludwig CU: Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res 57(17): 3669-3671, 1997. (Pubitemid 27381205)
31. Battling B, Hofmann HS, Weigle B, Silber RE and Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26(2): 293-301, 2005. (Pubitemid 40246550)
32. Bartling B, Demling N, Silber RE and Simm A: Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol 34(1): 83-91, 2006. (Pubitemid 43042860)
33. Shen X, Hong L, Sun H, Shi M and Song Y: The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep 22(3): 535-539, 2009.
34. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C and Bullerdiek J: Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 49(6): 1184-1189, 2008. (Pubitemid 351943266)
35. Sterenczak KA, Joetzke AE, Willenbrock S, Eberle N, Lange S, Junghanss C, Nolte I, Bullerdiek J, Simon D and Murua Escobar H: High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma. Anticancer Res 30(12): 5043-5048, 2011.
36. Padgett GA, Madewell BR, Keller ET, Jodar L and Packard M: Inheritance of histiocytosis in Bernese mountain dogs. J Small Anim Pract 36(3): 93-98, 1995.
37. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y and Lebecque S: Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178(5): 2763-2769, 2001.
38. Simonetti O, Goteri G, Lucarini G, Rubini C, Stramazzotti D, Lo Muzio L, Biagini G and Offidani A: In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness:an immunohistochemical study. Int Journal Immunopathol Pharmacol 20(2): 325-333, 2007.
39. Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337(1-2): 251-258, 2010.
40. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A and Bianchi ME: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J 22(20): 5551-5560, 2003. (Pubitemid 37279964)
41. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME and Rubartelli A: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. Embo Rep 3(10): 995-1001, 2002. (Pubitemid 35256475)